Detalles de la búsqueda
1.
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
N Engl J Med;
387(20): 1855-1864, 2022 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36342163
2.
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE).
Am Heart J;
251: 61-69, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35588897
3.
Long-Term Levels of LDL-C and Cognitive Function: The CARDIA Study.
J Int Neuropsychol Soc;
27(10): 1048-1057, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33563358
4.
Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation.
Circulation;
140(17): 1426-1436, 2019 10 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31634011
5.
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Eur Heart J;
40(33): 2775-2781, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30561610
6.
Evolocumab: Considerations for the Management of Hyperlipidemia.
Curr Atheroscler Rep;
20(4): 17, 2018 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29511875
7.
One-Year Efficacy and Safety of Evolocumab in Japanese Patientsã- A Pooled Analysis From the Open-Label Extension OSLER Studies.
Circ J;
81(7): 1029-1035, 2017 Jun 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28367845
8.
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Am Heart J;
176: 83-92, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27264224
9.
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
JAMA;
316(22): 2373-2384, 2016 12 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27846344
10.
Ancestral diversity in lipoprotein(a) studies helps address evidence gaps.
Open Heart;
10(2)2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37648373
11.
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).
Nat Med;
28(1): 96-103, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35027752
12.
Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study.
Cardiovasc Diagn Ther;
11(1): 120-129, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33708484
13.
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091].
Am J Prev Cardiol;
6: 100153, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34374706
14.
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV.
Am J Prev Cardiol;
3: 100091, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34327467
15.
Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.
J Am Heart Assoc;
8(4): e010932, 2019 02 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30755061
16.
Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies.
Clin Cardiol;
41(10): 1328-1335, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30120772
17.
Effect of Evolocumab on Coronary Plaque Composition.
J Am Coll Cardiol;
72(17): 2012-2021, 2018 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30336824
18.
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
JAMA Cardiol;
2(6): 598-607, 2017 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28291870
19.
Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab.
JACC Cardiovasc Imaging;
15(4): 709-711, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34922870
20.
Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review.
Curr Med Res Opin;
32(6): 1143-50, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26949994